Oracle Runs

Oracle findings and outcome history for Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma (NCT05251259).

Runs

Findings

Latest Run

Apr 6, 2026, 2:57 PM

All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial completed Jan 2026 per sponsor site (primary/study completion 2026-01-07). No public readout found: no topline press release, no efficacy data on ClinicalTrials.gov or AstraZeneca results summary (documents pending). AZ pipeline Feb 2026 lists it in Ph2 without readout note. Evidence incomplete, no clear positive/negative framing.

Found Apr 6, 2026, 2:57 PMReviewed Apr 6, 2026, 3:00 PM

Sponsorastrazenecaclinicaltrials.comJan 1, 2026, 12:00 AM

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

Study status: Complete. Primary Completion Date: 07 Jan 2026; Study Completion Date: 07 Jan 2026. Trial Results Summaries available but no efficacy data posted.

Sponsorastrazeneca.trialsummaries.com

TrialSummaries.com - Study to Assess the Efficacy and Safety of Atuliflapon

No documents posted yet. Results Summary: please see Sponsor contact section. Primary Completion Jan 2026.

Web Searchtheglobeandmail.comJan 15, 2026, 12:00 AM

AstraZeneca's Atuliflapon Asthma Trial Reaches Completion

Trial reaches completion. While no results are posted yet, investors should watch for upcoming data.

NO_DECISIONDismissed85% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial completed Jan 2026 (primary and study completion). No public results, efficacy data, or sponsor readout found on ClinicalTrials.gov, AZ site, or news. Sources are pre-results or speculative about potential. No clear positive/negative framing of this exact trial's outcome.

Found Apr 6, 2026, 2:08 PMReviewed Apr 6, 2026, 2:23 PM

Web Searchclinicaltrials.gov

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

Study complete. Primary completion 2026-01-07. No results posted.

Web Searchastrazenecaclinicaltrials.com

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma - FLASH

Study Complete, primary completion Jan 2026. Trial results summaries link present but no data posted.

Web Searchtheglobeandmail.comJan 15, 2026, 12:00 AM

AstraZeneca's Atuliflapon Asthma Trial Reaches Completion - What Investors Should Watch Next

Trial reached completion. Discusses potential positive outcome for market but reports no actual results.

NO_DECISIONDismissed80% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov lists this study as completed but without posted results, so there is no clear public trial-specific basis yet to call the readout positive or negative.

Found Apr 4, 2026, 8:52 PMReviewed Apr 4, 2026, 10:33 PM

ClinicalTrialsclinicaltrials.govJan 14, 2026, 12:00 AM

Study Details | NCT05251259 | ClinicalTrials.gov

ClinicalTrials.gov lists completed; primary completion 2026-01-07; hasResults=false on the latest posted update.

NO_DECISIONDismissed90% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No clear public efficacy readout found for this exact Phase 2 trial. AstraZeneca’s own trial-summary page says no result documents have been posted yet, and AstraZeneca’s Feb 10, 2026 pipeline still lists atuliflapon in Phase II. With no trial-specific positive/negative framing, outcome is not publicly classifiable.

Found Apr 2, 2026, 5:15 PMReviewed Apr 3, 2026, 4:48 PM

Sponsorastrazeneca.trialsummaries.com

TrialSummaries.com - Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

AstraZeneca-hosted trial summary page for D7552C00001/NCT05251259 shows start January 2022, completion January 2026, and states: no documents have been posted yet.

Sponsorastrazeneca.comFeb 10, 2026, 12:00 AM

Pipeline - AstraZeneca

AstraZeneca pipeline page, dated 10 February 2026, still lists atuliflapon for asthma under Phase II, without any linked trial-specific efficacy interpretation.

Sponsorastrazenecaclinicaltrials.com

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

AstraZeneca clinical trial page identifies NCT05251259 as Phase 2, Study Complete, with primary and study completion dates of 07 January 2026; it links to a results-summary area but provides no posted efficacy publication on-page.

NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

The exact Phase 2 asthma trial is marked complete as of January 7, 2026, but AstraZeneca’s linked TrialSummaries page says no documents have been posted yet. I found no cited public readout framing this specific trial as positive or negative, so the outcome remains unclassified.

Found Mar 31, 2026, 9:49 PMReviewed Apr 1, 2026, 6:34 AM

Sponsorastrazenecaclinicaltrials.com

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma - FLASH

AstraZeneca’s study page for NCT05251259 shows Study Complete, Phase 2, with Primary Completion Date January 7, 2026 and Study Completion Date January 7, 2026.

Sponsorastrazeneca.trialsummaries.com

TrialSummaries.com - Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

AstraZeneca’s linked Trial Results Summary page for this exact study lists the trial identifiers and dates, then states: No documents have been posted yet.

Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.